Näytteistä tutkittua tietoa

Väitöskirjat / Doktorsavhandlingar / Dissertations

2021: Eleonora Mäkelä: Novel PP2A biomarkers in cancer

2020: Ciara Tierney: Proteomic Characterisation of Patient Samples Diagnosed with Haematological Malignancies

2019: Ashwini Kumar: Transcriptomic data integration for precision medicine in leukemia

2019: Heta Tarkkala: Reorganizing Biomedical Research Biobanks as Conditions of Possibility for Personalized Medicin

2017: Mika Kontro: Individualizing therapy fo acute leukemia


Tutkimukset / Studier / Studies


Eldfors et al: Monosomy 7/del(7q) Cause Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia. Blood Adv 2024; bloodadvances.2023010435. doi: https://doi.org/10.1182/bloodadvances.2023010435


Casado et al 2023: Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes. Sig Transduct Target Ther 8, 80. https://doi.org/10.1038/s41392-022-01288-1

Lahtinen et al 2023: Clinically relevant germline variants in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 58, 39–45. https://doi.org/10.1038/s41409-022-01828-x

Valkama et al 2023: Optical Genome Mapping as an Alternative to FISH-Based Cytogenetic Assessment in Chronic Lymphocytic Leukemia. Cancers 15(4):1294. https://doi.org/10.3390/cancers15041294


Kelkka et al 2022: Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia. Leukemia 36, 2317–2327. https://doi.org/10.1038/s41375-022-01654-6

Douglas et al 2022: Enrichment of cancer-predisposing germline variants in adult and pediatric patients with acute lymphoblastic leukemia. Scientific Reports 12(1):10670. doi: 10.1038/s41598-022-14364-x

Velasco-Hernandez et al 2022: A comprehensive single-cell expression atlas of human AML leukemia-initiating cells unravels the contribution of HIF pathway and its therapeutic potential. bioRxiv 2022.03.02.482638; doi: https://doi.org/10.1101/2022.03.02.482638

Flanagan et al 2022: The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death. HemaSphere 6 (3). https://doi.org/10.1097/HS9.0000000000000687

Hohtari et al 2022: Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 107(8):1971-1976. https://doi.org/10.3324/haematol.2021.280578

Hohtari et al 2022: Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. Hemasphere 6 (3). https://doi:10.1097/HS9.0000000000000701


Dowling et al 2021: Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches. Proteomes 9 (4); 42. https://doi.org/10.3390/proteomes9040042

IIanevski et al 2021: Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science advances 7 (8). https://doi.org/10.1126/sciadv.abe4038

Liu, Minxia el al 2021: S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma. Frontiers in Cell and Developmental Biology 9. https://doi.org/10.3389/fcell.2021.723016

Lundgren et al 2021: Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. Leukemia 35; 1365-1379. https://doi.org/10.1038/s41375-021-01231-3

Miettinen et al 2021: Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. Cancers 13 (7); 1527. https://doi.org/10.3390/cancers13071527

Mäkelä et al 2021: Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. Clin Cancer Res 27 (10); 2848-2860. https://doi.org/10.1158/1078-0432.CCR-20-3679


Douglas et al 2019: ERCC6L2 defines a novel entity within inherited acute myeloid leukemia. Blood 133 (25); 2724-2728. https://doi.org/10.1182/blood-2019-01-896233

Dufva et al 2019: Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity. Blood 135 (9); 597-609. https://doi.org/10.1182/blood.2019002121

Hohtari et al 2019: Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. Leukemia 33; 1570-1582. https://doi.org/10.1038/s41375-018-0360-1

Mäkelä et al 2019: Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia. Cancers 11; 1774. https://doi.org/10.3390/cancers11111774


Wartiovaara-Kautto et al 2018: Germline alterations in a consecutive series of acute myeloid leukemia. Leukemia 32;2282-2285. https://doi.org/10.1038/s41375-018-0049-5